MENU

Can MediWound (MDWD) Stock Reach $30?

a biopharmaceutical company

A.I.Advisor
published price charts
A.I.Advisor
Nov 12, 2026

Can MediWound (MDWD) Stock Reach $30?

MediWound Ltd. (MDWD), an Israeli biopharmaceutical company developing enzymatic, non-surgical therapies for tissue repair, has seen its shares trade well below the levels implied by the analyst price targets that Wall Street currently publishes. The central question for investors is whether the stock can climb toward a $30 target — a figure that would require a move of roughly 131% from recent prices.

Key Takeaways

  • The $30 central target is the arithmetic mean of five verified analyst price targets, rounded from a calculated average of $29.60.
  • Recent share prices around $12.97 leave an implied upside of about 131% to reach $30 — a very large move by any standard.
  • The analyst target range is wide, spanning approximately $25 to $36, reflecting sharp disagreement over the value of the EscharEx pipeline.
  • The strongest support comes from the late-stage EscharEx Phase III VALUE trial and growing NexoBrid commercial traction through partner Vericel.
  • The biggest risks are declining revenue, heavy reliance on U.S. government development services, cash burn, and recent dilution.
  • For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
  • To see how AI evaluates changing market conditions across thousands of tickers, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Five current, attributable price targets were reviewed to build the central figure. H.C. Wainwright holds a Buy rating with a $36 target, while Maxim Group and Oppenheimer each carry $30 targets, Alliance Global Partners has a $27 target, and TD Cowen has a $25 target. Averaging these five values produces $29.60, which rounds to the $30 central target used here. The low-to-high range of $25 to $36 underscores how much analyst opinion diverges.

The ratings skew heavily bullish — a "Strong Buy" orientation with no Holds or Sells among recently reporting firms — but the wide spread reflects genuine uncertainty. Bullish analysts emphasize the potential of EscharEx, an investigational therapy for debridement of chronic wounds, whose U.S. peak-sales opportunity management has estimated at roughly $1.05 billion after adding pressure ulcers to the analysis. More cautious targets acknowledge that the company's current revenue is shrinking and that the pivotal clinical readout remains in the future.

Current Market Position and Path Toward the Target

With shares recently trading near $12.97 and a 52-week range of roughly $11.80 to $19.70, the stock sits well below both its yearly high and the $30 target. Reaching $30 would require a gain of about 131%, which must be classified as a very large move rather than a modest one.

The company reported third-quarter 2026 revenue of $3.6 million, down from $5.4 million a year earlier, and a net loss of $6.0 million, or $0.47 per share. Revenue remains heavily weighted toward development services tied to U.S. government programs, while product sales are constrained by manufacturing capacity rather than demand. Any path toward $30 would likely require a successful EscharEx VALUE trial readout, a resumption of revenue growth, and continued NexoBrid adoption.

What Could Support a Move Toward the Target

Several verified factors underpin the bullish case. EscharEx's global Phase III VALUE trial in venous leg ulcers, targeting 216 patients, is expected to reach its interim sample-size assessment and complete enrollment by the first quarter of 2027, with top-line data to follow. Management has guided to substantial revenue growth in coming years — $24–26 million in 2026, $32–35 million in 2027, and $50–55 million in 2028 — contingent on U.S. government support and potential EscharEx contributions.

NexoBrid, the company's FDA-approved biologic for removal of eschar in thermal burns, is gaining commercial traction. Partner Vericel (VCEL) reported NexoBrid's strongest quarter since launch, with more than 80 burn centers ordering to date. A BARDA framework valued at up to $197 million and non-dilutive U.S. Department of Defense funding for a room-temperature formulation broaden the opportunity set.

What Could Prevent the Target From Being Reached

The risks are material. Revenue fell sharply in 2026 — $8.1 million in the first nine months versus $15.1 million a year earlier — because development-services revenue declined. Cash, equivalents, and deposits totaled $28.4 million at the end of September 2026 after $28.3 million of cash burn in nine months, and the company closed a $17.25 million public offering in November, adding dilution.

Clinical risk is the central variable: a disappointing or inconclusive VALUE trial readout, a required expansion of the sample size, or regulatory delays could reset expectations. NexoBrid supply is capacity-limited, and expanded-facility commercial supply is not expected until the second half of 2027. Competition in wound debridement, including Smith & Nephew's SANTYL franchise, also persists.

Technical Levels and Market Structure

The stock's 52-week low near $11.80 marks a key support level, while the yearly high near $19.70 represents a durable resistance zone. Between current prices and $30, there is little established trading history, meaning the $20 area and any psychological round numbers would be watched as potential resistance on a recovery. The long-term trend has been negative, with the shares down roughly 25% to 30% over the past year.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of about 12 months, though this is an assumption and individual firms' horizons can differ. The most consequential upcoming items are the EscharEx VALUE trial interim assessment and enrollment completion expected by the first quarter of 2027, followed by top-line data, plus NexoBrid regulatory approvals for the expanded manufacturing facility and the resolution of U.S. government funding discussions. Quarterly revenue trends, cash position, and any further financing will also matter.

AI Daily Buy/Sell Signals

Investors tracking a volatile, event-driven name like MDWD may also monitor AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use it to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than scanning charts manually. Exploring these signals can help put a developing price move into broader context.

Final Assessment

The $30 target is the rounded average of five current analyst price targets spanning roughly $25 to $36. From a recent price near $12.97, reaching it would require a gain of about 131% — a very large move that would depend heavily on the EscharEx VALUE trial delivering positive results and on NexoBrid's commercial ramp accelerating. Supporters point to a large chronic-wound market opportunity and growing government backing, while skeptics emphasize shrinking revenue, cash burn, and dilution. The wide analyst range shows genuine disagreement, and no outcome is guaranteed; the EscharEx readout and near-term revenue trajectory are the key data points to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

MDWD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MDWD has been loosely correlated with BCYC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MDWD jumps, then BCYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDWD
1D Price
Change %
MDWD100%
+0.37%
BCYC - MDWD
37%
Loosely correlated
-4.92%
LXEO - MDWD
36%
Loosely correlated
+0.34%
GMAB - MDWD
35%
Loosely correlated
-1.46%
DMAC - MDWD
34%
Loosely correlated
+2.87%
ABUS - MDWD
34%
Loosely correlated
-1.23%
More
Can MediWound (MDWD) Stock Reach $30?